

Compendial Cancellations for USP 35–NF 30

Monograph Title	Monograph Section	Scientific Liaison
<1113> MICROBIAL IDENTIFICATION PF 35(1) Pg. 167	Title, INTRODUCTION, MICROBIAL ISOLATION, PRELIMINARY SCREENING OF MICROBIAL ISOLATES, MICROBIAL IDENTIFICATION BY PHENOTYPIC METHODS, MICROBIAL IDENTIFICATION BY GENOTYPIC METHODS, VERIFICATION OF MICROBIAL IDENTIFICATION METHODS IDENTIFICATION/Introduction, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Dioxide, IMPURITIES/Inorganic Impurities/Sample, IMPURITIES/Inorganic Impurities/Analysis, IMPURITIES/Inorganic Impurities/Acceptance criteria, IMPURITIES/Inorganic Impurities/Carbon Monoxide, IMPURITIES/Inorganic Impurities/Sulfur Dioxide, IMPURITIES/Inorganic Impurities/Limit of Nitric Oxide and Nitrogen Dioxide, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling	Radhakrishna Tirumalai
MEDICAL AIR PF 35(4) Pg. 828	PERFORMANCE TESTS/Dissolution <711>	Ravi Ravichandran
ALENDRONATE SODIUM TABLETS PF 36(5) Pg. 1157	DEFINITION/Introduction, ASSAY/Procedure	Elena Gonikberg
BUDESONIDE PF 36(6) Pg. 1504	Title, Definition, Packaging and storage, Labeling, USP Reference standards <11>, Identification, Dissolution <711> - Test 1, Dissolution <711> - Test 2, Dissolution <711> - Test 3, Uniformity of dosage units <905>, Related compounds, Assay	Domenick Vicchio
CARBIDOPA AND LEVODOPA EXTENDED-RELEASE TABLETS PF 34(6) Pg. 1433	Milbemycin Oxime, Albumin Human	Ravi Ravichandran
DESCRIPTION AND SOLUBILITY PF 36(2) Pg. 578	SPECIFIC TESTS/PH <791> (for the Injection labeled as one-vial formulation), SPECIFIC TESTS/PH <791> (for the Injection labeled as two-vial formulation)	Morgan Puderbaugh
DOCETAXEL INJECTION PF 37(1) Pg. ONLINE	IDENTIFICATION/A., IDENTIFICATION/B., IDENTIFICATION/Introduction, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Monoxide, IMPURITIES/Inorganic Impurities/Acceptance criteria, SPECIFIC TESTS/Odor, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling	Feiwen Mao
HELIOX PF 35(4) Pg. 850	Title, Definition, Packaging and storage, USP Reference standards <11>, Identification, Dissolution <711>, Uniformity of dosage units <905>, Loss on drying <731>, Loratadine chromatographic purity, Pseudoephedrine sulfate chromatographic purity, Assay for loratadine, Assay for pseudoephedrine sulfate	Ravi Ravichandran
LORATADINE AND PSEUDOEPHEDRINE SULFATE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1715	Title, Chemical Info/Chemical Structure, Chemical Info/C31H43NO7 (Milbemycin A3 Oxime), Chemical Info/541.68, Chemical Info/Milbemycin B, 5-O-demethyl-28-deoxy-25-methyl-6,28-epoxy-23-hydroxyimino-, [6R,23S,25S(E)]-;, Chemical Info/(2αE,4E,5′S,6R,6′S,8E,11R,13R,15S,17&a mp;alpha;R,20αR,20βS)-6′-ethyl-3′;, 4′,5′;,6,6′;,7,10,11,14,15,17α,20,2	Mary Waddell

0α,20β-tetradecahydro-20β-hydroxy-5′;,6,8,19-tetramethylspiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2′-[2H]pyran]-17-one 20-oxime;, Chemical Info/(1R, 4S, 5′S, 6R, 6′R, 8R, 13R, 20R, 24S, 10E, 14E, 16E, 22Z)-24-hydroxy-21-hydroxyimino-2-oxo-11, 13, 22-trimethyl-3, 7, 19-trioxatetracyclo-[15, 6, 1,14,8,020,24] pentacosa-10, 14, 16, 22-tetraene-6-spiro-2′-(5,′6′-dimethyltetrahydropyran), Chemical Info/C32H45NO7 (Milbemycin A4 Oxime), Chemical Info/555.70, Chemical Info/Milbemycin B, 5-O-demethyl-28-deoxy-25-ethyl-6,28-epoxy-23-hydroxyimino-, [6R,23S,25S(E)]-;, Chemical Info/(2αE,4E,5′S,6R,6′S,8E,11R,13R,15S,17&a mp;αR,20αR,20βS)-6′-3′4′5′,6,6′,7,10,11,14,15,17α,20,20α,20β-tetradecahydro-20β-hydroxy-5′,6&am p;′,6,8,19-pentamethylspiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2′-[2H]pyran]-17-one 20-oxime;, Chemical Info/(1R, 4S, 5′S, 6R, 6′R, 8R, 13R, 20R, 24S, 10E, 14E, 16E, 22Z)-24-hydroxy-21-hydroxyimino-2-oxo-11, 13, 22-trimethyl-3, 7, 19-trioxatetracyclo-[15, 6, 1,14,8,020,24] pentacosa-10, 14, 16, 22-tetraene-6-spiro-2′-(6′-ethyl-5′-methyltetrahydropyran);, Chemical Info/Mixture of milbemycin A3 oxime and milbemycin A4 oxime, Chemical Info/CAS, DEFINITION/Introduction, IDENTIFICATION/A. Infrared Absorption <197K>, IDENTIFICATION/B., ASSAY/Procedure, IMPURITIES/Organic Impurities/Procedure, SPECIFIC TESTS/Water Determination, Method I <921>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Milbemycin Oxime RS

NITROGEN PF 35(4) Pg. 910
IDENTIFICATION/Introduction, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Monoxide, SPECIFIC TESTS/Odor, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling

[Ravi](#)
[Ravichandran](#)

NITROGEN 97 PERCENT PF 35(4) Pg. 911
DEFINITION/Introduction, IDENTIFICATION/Introduction, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Dioxide, IMPURITIES/Inorganic Impurities/Carbon Monoxide, IMPURITIES/Inorganic Impurities/Sulfur Dioxide, IMPURITIES/Inorganic Impurities/Limit of Nitric Oxide and Nitrogen Dioxide, ADDITIONAL REQUIREMENTS/Packaging and Storage

[Ravi](#)
[Ravichandran](#)

NITROUS OXIDE PF 35(4) Pg. 859
DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., IDENTIFICATION/C., ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Ammonia, IMPURITIES/Inorganic Impurities/Nitric Oxide, IMPURITIES/Inorganic Impurities/Nitrogen Dioxide, IMPURITIES/Inorganic Impurities/Halogens, IMPURITIES/Inorganic Impurities/Carbon Monoxide, IMPURITIES/Inorganic Impurities/Carbon Dioxide, SPECIFIC TESTS/Water, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling

[Ravi](#)
[Ravichandran](#)

NONYLPARABEN PF 36(2) Pg. Nonylparaben (4-Hydroxybenzoic acid nonyl ester, nonyl 4-

[Morgan](#)

575

OXCARBAZEPINE TABLETS
PF 34(6) Pg. 1478

hydroxybenzoate),

Title, Definition, Packaging and storage, USP Reference standards <11>, Identification, Uniformity of dosage units <905>, Related compounds, Assay

[Puderbaugh](#)

[Ravi](#)
[Ravichandran](#)

OXYGEN PF 35(4) Pg. 861

IDENTIFICATION/Procedure, IDENTIFICATION/B. Procedure, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Dioxide, IMPURITIES/Inorganic Impurities/Carbon Monoxide, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling

OXYGEN 93 PERCENT PF
35(4) Pg. 862

IDENTIFICATION/A. Procedure, IDENTIFICATION/B. Procedure, ASSAY/Procedure, IMPURITIES/Inorganic Impurities/Carbon Dioxide, IMPURITIES/Inorganic Impurities/Carbon Monoxide, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling

[Ravi](#)
[Ravichandran](#)

PANCURONIUM BROMIDE
INJECTION PF 32(4) Pg. 1097

Title, Definition, Packaging and storage, USP Reference standards <11>, Identification, pH <791>, Particulate matter <788>, Related compounds, Other requirements, Assay

[Mary](#)
[Waddell](#)

SUMATRIPTAN TABLETS PF
35(4) Pg. 871

IMPURITIES/Organic Impurities/Procedure

[Ravi](#)
[Ravichandran](#)

TEMAZEPAM PF 36(6) Pg.
1574

ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Temazepam Related Compound G RS 7-Chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione. C17H15ClN2O2314.77

[Hariram](#)
[Ramanathan](#)

VINCRISTINE SULFATE PF
37(1) Pg. ONLINE

Chemical Info/Chemical Structure, ASSAY/Procedure, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Vincristine Sulfate (Assay) RS. Note—It is not intended for use in Identification test A.

[Feiwen Mao](#)

VINCRISTINE SULFATE
INJECTION PF 37(1) Pg.
ONLINE

IDENTIFICATION/A. Thin-Layer Chromatographic Identification Test <201>, ASSAY/Procedure, IMPURITIES/Organic Impurities/Solution C, IMPURITIES/Organic Impurities/Analysis, IMPURITIES/Organic Impurities/Acceptance criteria, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Vincristine Sulfate (Assay) RS

[Feiwen Mao](#)

VINCRISTINE SULFATE FOR
INJECTION PF 37(1) Pg.
ONLINE

IDENTIFICATION/A. Thin-Layer Chromatographic Identification Test <201>, ASSAY/Procedure, PERFORMANCE TESTS/Uniformity of Dosage Units, Content Uniformity <905>, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Vincristine Sulfate (Assay) RS

[Feiwen Mao](#)